Twenty-seven states and D.C. sued to prevent 23andMe from selling customer genetic data without consent during its bankruptcy proceedings. The lawsuit argues that biological samples and related information are too sensitive for sale without explicit consent. 23andMe, facing financial struggles, filed for Chapter 11 bankruptcy and is being acquired by Regeneron Pharmaceuticals for $256 million. Regeneron claims it will respect existing privacy policies, while a court-appointed ombudsman is reviewing the sale's impact on consumer privacy.

Prepared by Jonathan Pierce and reviewed by editorial team.